Publications by authors named "Fabian Franzen"
Article Synopsis
- The phase 2 CLL2-BAAG trial evaluated a combination therapy of acalabrutinib, venetoclax, and obinutuzumab in 45 patients with relapsed/refractory chronic lymphocytic leukemia (CLL), focusing on measurable residual disease (MRD) outcomes.
- 93.3% of patients achieved undetectable MRD (<10-4) at any time point, showing the treatment's effectiveness, including those previously exposed to other therapies.
- The study indicated high 3-year progression-free and overall survival rates (85.0% and 93.8%, respectively) and highlighted that integrating circulating tumor DNA (ctDNA) analysis with traditional methods improved early relapse detection
Although several promising approaches for the treatment of relapsed/refractory diffuse large B-cell lymphoma (rrDLBCL) have been approved recently, it remains unclear which patients will ultimately achieve long-term responses. Circulating tumor (ct)DNA sequencing has emerged as a valuable tool to assess minimal residual disease (MRD). Correlations between MRD and outcomes have been shown in previously untreated DLBCL, but data on the repeated assessment of MRD in the dynamic course of rrDLBCL is limited.
View Article and Find Full Text PDFArticle Synopsis
- More than 99% of cervical cancers and 40% of vulvar cancers are caused by a virus called HPV, especially types 16 and 18.
- Scientists are testing a new way to detect tiny bits of HPV DNA in blood to help monitor cancer treatment.
- They found that the amount of HPV DNA in the blood dropped a lot after treatment, indicating that this method could help doctors see if the treatment is working, especially for more advanced cancer cases.
Purpose: With the advent of highly efficacious time-limited combination treatments of targeted agents in chronic lymphocytic leukemia (CLL), minimal residual disease (MRD) assessment has gained importance as a measure for therapeutic success and as a surrogate for progression-free survival. The currently most widely used method is multicolor flow cytometry, which detects circulating CLL cells in the peripheral blood. However, it seems to be less sensitive for the detection of MRD in the lymph node compartment.
View Article and Find Full Text PDF